These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 10876750

  • 1. [Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
    Maekawa S, Suzuki H, Ohkubo K, Aoki Y, Okada T, Maeda H, Ogura K, Arai Y.
    Hinyokika Kiyo; 2000 May; 46(5):301-6. PubMed ID: 10876750
    [Abstract] [Full Text] [Related]

  • 2. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B, el-Baz M, Aly AN, Shamaa S, Ashamallah A.
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S.
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [Abstract] [Full Text] [Related]

  • 4. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
    Segawa N, Nishida T, Takahara K, Nomi H, Azuma H, Katsuoka Y.
    Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
    [Abstract] [Full Text] [Related]

  • 5. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C, Sato K, Kato T.
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [Abstract] [Full Text] [Related]

  • 6. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M, Sugaya Y, Yuzawa M, Morita T, Kobayashi Y, Tokue A.
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [Abstract] [Full Text] [Related]

  • 7. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M, Mian C, Negri G, Vittadello F, Comploj E, Palermo S, Staffler A, Brössner C, Pycha A.
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [Abstract] [Full Text] [Related]

  • 8. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
    Kuroda K, Ishii N, Fukasawa K, Shirai M, Tajima M, Matsushima M, Miura K, Takanami M, Matsuhashi M, Kuwabara T, Matsumoto H, Sugita M.
    Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
    Liu B, Wang Z, Chen B, Yu J, Zhang P, Ding Q, Zhang Y.
    Cancer Invest; 2006 Mar; 24(2):160-3. PubMed ID: 16537185
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences.
    Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmäng S.
    J Urol; 2008 Jan; 179(1):101-5; discussion 105-6. PubMed ID: 17997459
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
    Pérez Mestre M, Cuñat Albert E, Francisco Mingol V, Arrufat Boix JM, Gallego Gómez J.
    Arch Esp Urol; 1999 May; 52(4):345-50. PubMed ID: 10380324
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
    Hinotsu S, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Obata K, Ohashi Y, Ohe H, Shimazaki J, Tashiro K, Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin.
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
    Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.
    Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
    [Abstract] [Full Text] [Related]

  • 20. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
    Hinotsu S, Akaza H, Ohashi Y, Kotake T.
    Cancer; 1999 Nov 01; 86(9):1818-26. PubMed ID: 10547556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.